Home 
CONTACT Neoplasma Ahead of print Neoplasma Vol.69, No.4, p.755–763, 2022
CONTACT Neoplasma Ahead of print Neoplasma Vol.69, No.4, p.755–763, 2022
Journal info
|
||
Select Journal
Journals
Bratislava Medical Journal Endocrine Regulations General Physiology and Biophysics Neoplasma 2024 Ahead of print 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 Acta Virologica Studia Psychologica Cardiology Letters Psychológia a patopsych. dieťaťa Kovove Materialy-Metallic Materials Slovenská hudbaWebshop Cart
Your Cart is currently empty.
Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.
Neoplasma Vol.69, No.4, p.755–763, 2022 |
||
| Title: Endothelial lipase promotes acute myeloid leukemia progression through metabolic reprogramming | ||
| Author: Si-Qi Shang, Ying Yang, Xue-Jiao Yang, Xiao-Dong Shi, Yun-Shuo Chen, Yue-Ying Wang | ||
| Abstract: Metabolic reprogramming occurs in the clonal evolution of acute myeloid leukemia (AML), which contributes to cell survival under metabolic stress and the development of drug resistance. Leukemic cells exhibit various metabolic profiles, which involve multiple metabolic pathways due to the heterogeneity of AML. However, studies on metabolic targets for AML treatment are mostly focused on glycolysis at present. In this work, we established conditional knock-in AML mouse models harboring Dnmt3aR878H/WT, NrasG12D/WT, and both of the mutations, respectively. Transcriptomic analysis of Gr1+ cells from bone marrow was performed afterward to screen interested metabolic pathways and target genes. Candidate genes were studied using the CRISPR/Cas9 technique, quantitative real-time RT-PCR, and flow cytometric analyses. We revealed that multiple metabolic pathways were affected in AML mice, including lipid metabolism. Endothelial lipase (LIPG) was obviously upregulated in leukemic cells from AML mice with Dnmt3a mutation. We performed knockout of LIPG in OCI-AML3 cells carrying DNMT3A R882C mutation by using the CRISPR/Cas9 technique. Depletion of LIPG led to proliferation inhibition, apoptosis, damage of antioxidant capacity, and myeloid differentiation in OCI-AML3 cells. LIPG might serve as a potential metabolic target for the treatment of AML with abnormal lipid metabolism. |
||
| Keywords: endothelial lipase; acute myeloid leukemia; lipid metabolism; DNA methyltransferase 3A | ||
| Published online: 10-Mar-2022 | ||
| Year: 2022, Volume: 69, Issue: 4 | Page From: 755, Page To: 763 | |
| doi:10.4149/neo_2022_211004N1408 |
||
|
|
 download file |
|